MedPath

OMICSWAY CORP.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

Conditions
Cancer
Interventions
Other: RNA sequencing
Other: Transcriptome analysis
Drug: palliative care
Drug: target drug with the score above 0,1
Drug: target drug with the score equal or below 0,1
Drug: non-target drug
First Posted Date
2018-10-30
Last Posted Date
2021-09-14
Lead Sponsor
OmicsWay Corp.
Target Recruit Count
200
Registration Number
NCT03724097
Locations
🇺🇸

OmicsWay Corp., Walnut, California, United States

🇷🇺

Kaluga Regional Clinical Oncology Center, Kaluga, Russian Federation

🇷🇺

Oncological Clinical Dispensary No. 1 of the Moscow City Health Department, Moscow, Russian Federation

and more 4 locations

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

Conditions
HER2-positive Breast Cancer
Interventions
Other: RNA sequencing
Other: Transcriptome analysis
Drug: Chemotherapy
First Posted Date
2018-05-11
Last Posted Date
2021-09-14
Lead Sponsor
OmicsWay Corp.
Target Recruit Count
40
Registration Number
NCT03521245
Locations
🇺🇸

OmicsWay Corp., Walnut, California, United States

🇷🇺

Republican Oncological Dispensary of the Ministry of Healthcare of Karelia Republic, Petrozavodsk, Karelia Republic, Russian Federation

🇷🇺

Vitamed LLC, Moscow, Russian Federation

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.